Plasma insulin-like growth factor I as predictor of progression and all cause mortality in chronic heart failure

Objectives: Insulin-like growth factor I (IGF-I) is an anabolic growth factor that seems to increase cardiac contractility. Reduced levels of IGF-I may be implicated in progression of CHF. The objective was to compare plasma IGF-I in CHF patients with healthy controls. and to examine the associations between baseline IGF-I levels, cardiac contractility and the prognosis as judged by all cause mortality and progression of CHIF requiring admission to hospital. Methods: A prospective study comprising 194 CHF outpatients, and 169 matched controls. All patients and controls underwent echocardiographic examination at baseline. Patients were followed for a median of 30 months. Results: There was no difference in IGF-I levels between patients and controls (median and interquartile range), 78 (58-91) vs. 77 (57-94) ng/mL (P = 0.92). Age-adjusted IGF-I levels were not related to left ventricular ejection fraction (LVEF) (P = 0.58) or levels of N-terminal B-Type natriuretic peptide (NT-proBNP) (P = 0.42). During follow-up 44 patients died and 94 were admitted to hospital due to worsening of CHF. Adjusted for cardiovascular risk factors (age, gender, NT-proBNP, lipids, diabetes mellitus, blood pressure, renal function and LVEF) IGF-I levels did not influence the overall mortality risk or the admission rate to hospital, hazard ratio (HR) (95% confidence intervals) 1.05 (0.75-1.47) (P = 0.77) and 1.00 (0.80-1.26) (P = 0.96), respectively per each SD increase in log IGF-I levels. Conclusions: IGF-I levels were not reduced in patients with CHF and did not influence cardiac status at baseline or the prognosis. (C) 2009 Elsevier Ltd. All rights reserved.